Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 23

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 23
---
 set forth in the adjacent column which we would have issued to the Selling Shareholder 
 based on the applicable assumed purchase price per share.                                                                                       |

| (3) | We will not receive any proceeds from the issuance of any Commitment Shares if issued to the Selling Shareholder                       
 to release the Company of its liability to pay the Commitment Fee. The proceeds reflected in this column would be reduced by an amount 
 equal to the product of the final Commitment Shares multiplied by the assumed purchase price per Depositary Share.                     |

| (4) | Represents the last reported sales price of our Depositary Shares on January 16, 2024, as reported by 
 NASDAQ, less a 5% discount.                                                                           |

| 17 |

<div align='center'>USE OF PROCEEDS</div>

We will not receive any of
the proceeds from the sale of Depositary Shares offered by the Selling Shareholder. In addition, we will not receive any proceeds from
the issuance or sale of the Commitment Shares if issued to the Selling Shareholder to release the Company of its liability to pay the
Commitment Fee. We may receive up to $35.0 million in aggregate gross proceeds from the Selling Shareholder under the Purchase Agreement
in connection with sales of our Depositary Shares to the Selling Shareholder pursuant to the Purchase Agreement after the date of this
prospectus. However, the actual proceeds may be less than this amount depending on the number of Depositary Shares sold and the price
at which the Depositary Shares are sold.

We intend to use any net proceeds
that we receive under the Purchase Agreement to fund our development programs, for working capital and other general corporate purposes.

The expected use of the net
proceeds from the offering represents our intentions based upon our current plans and business conditions, which could change in the future
as our plans and business conditions evolve. The amounts and timing of our actual expenditures depend on numerous factors, including the
ongoing status of and results from our clinical trials and other studies, the progress of our preclinical development efforts and any
unforeseen cash needs. As a result, our management will have broad discretion in applying the net proceeds of the offerings.

Pending the uses described
above, we plan to invest the net proceeds from this offering in short-term, interest-bearing investments.

| 18 |

<div align='center'>DIVIDEND POLICY</div>

Since
inception, we have never declared or paid any cash dividends on our Ordinary Shares